Sun, Mar 1, 2015, 8:26 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Muscle Pharm Corp. Message Board

joejoepepitone 34 posts  |  Last Activity: 20 hours ago Member since: Dec 1, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • joejoepepitone joejoepepitone Dec 16, 2014 11:16 AM Flag

    They're paying $2. They could have bought Under the market. Novartis is #1. Jackpot. $10 18-24 months.

  • joejoepepitone by joejoepepitone Feb 11, 2015 11:02 AM Flag

    Look at BPI Sports website video, minute 4 20. They show the use of the CDXC seal. They are making it part of their marketing plan. Competitors will HAVE to follow, both for competitive as well as legal reasons (see NYS Atty General investigation). This will impact all the nutraceutical mfg, retailers, ie. Walgreens, CVS, Target, WalMart, GNC, Herbalife, Nature's Bounty, you name it. No one will want to leave themselves exposed. This will be a multi-million dollar, virtually pure profit, opportunity that has fallen in CDXC' lap. Incredible good fortune that was totally unforeseeable just several weeks ago. Above and beyond all the great stuff with NR, which will probably take some time before revenues are realized. The seal opportunity will more than carry them through until NR kicks in. CDXC has gone from bunt single, to double, and now lined up with NR, to be a 4 bagger.

  • Reply to

    Insights for New Shareholders

    by goutah3006 Feb 13, 2015 5:23 PM
    joejoepepitone joejoepepitone Feb 13, 2015 10:46 PM Flag

    #5. Seems like a binary event holding. Why invest in a coin toss? If it is scraping along as a penny stock, perhaps. Now it appears mortally wounded, with significantly less than 50% probability of survival. The upside seems a potential merger into another company over the course of time. Why bother with this? I sold and broke even, looking to get back around this level. Now that its arrived, I can't reason why it shouldn't be cut another 50%+.

  • joejoepepitone by joejoepepitone Feb 11, 2015 2:05 PM Flag

    From Today's Release:

    Frank - -"this study opens the door to the development of both consumer products and pharmaceuticals addressing these conditions"

    Another couple months and we start the releases from the mega's…P&G, J&J, NVS, NSRGY, Lever, etc. etc. 2015 is going to be a great year for CDXC. I am sure that Frank had NDA development deals well underway throughout 2013/2014. This conclusion of the study/results, officially turns on project approvals/introduction timetables at company HQ's for these giants.

  • Reply to

    I put the news release up, guess yoohoo

    by cl124cl Feb 11, 2015 10:41 AM
    joejoepepitone joejoepepitone Feb 17, 2015 3:49 PM Flag

    Price reacting to Cox article that has now been sent out officially by the IR Group(s), and upcoming news releases that will be much more numerous, and significant. I think we'll be up significantly once some of the Science Journals start to publish results. Will look forward to another research report written at some point.

  • Mauldineconomics Transformational Technologies
    Huge article on NR. Referenced the CDXC press release. Next issue to feature Dr. Frost. Would expect CDXC to possibly be a portfolio pick by P. Cox, and therefor receive lots more attention.Tens of thousands of readers, KOL's among them. If this gets picked up by Dr. Oz, etc., we go viral. We are almost there…much faster than expected. Big, big, opportunity for appreciation from here. GLTA

  • joejoepepitone by joejoepepitone Feb 10, 2015 1:14 PM Flag

    Something is brewing. This afternoon from their IR :

    ...After 13 months of not working with CDXC on the Investor Relations, have been rehired. Could not be more excited about the prospects for Chromadex over the next 1-2 years...

    My take is that a string of good news is around the corner. Corner, 3-6 months? Stuff has been percolating over the past 12 months and it's reasonable to assume that the company was gagged by its customers from discussing, therefore the termination of the IR group. The situation appears to have changed, and the IR group's cost expenditure to CDXC can now be rationalized. I think Frank's hire of the IR group says loudly and clearly that we're getting ready (or are already there) for Prime Time. All IMHO ( I expected 2014 to be the breakout, but I'll gladly take 2015!). Loaded for Bear…Double Target $2.50+ by Fall, if not much sooner.

  • Reply to

    Massive Verification Seal Opportunity

    by joejoepepitone Feb 11, 2015 11:02 AM
    joejoepepitone joejoepepitone Feb 11, 2015 11:42 AM Flag

    I don't think they need any sales force to serve this up and manage. It's a contract for the use of the seal that will be handled through invoicing against customers' production runs. I am sure that they are already insured, but will likely need to increase coverage. They already have the facility to do this, but will need to add some capacity or manpower to accommodate a surge of business. They absolutely are going to work hard to make this happen. This is huge. What the NYS Atty Genl did was just a sign of the times. CDXC is in the right spot to take immediate advantage of everyone's worst fears about products being pulled off shelves.

  • joejoepepitone by joejoepepitone Feb 19, 2015 11:18 AM Flag

    I see the CFO just signed up with another AZ company. This goes to a dime in March.

  • Reply to

    No CHP=greater tax loss selling

    by joejoepepitone Nov 22, 2014 11:03 AM
    joejoepepitone joejoepepitone Dec 4, 2014 10:51 AM Flag

    I was off on the sub-$1.00 achievement by a couple days. With tax loss selling, and plant #1 not "expected" until Q1 (March?), I'll split the difference ($.30 downside risk - $.95 today) with target downside of $.65 by December 31. Unless there is major news over the next 3 weeks, we are getting there….unfortunately my basis is over $2. Today's price at $.95………….at a all-time market high.

  • Reply to

    MRA Research

    by theeckman1 Dec 5, 2014 2:58 PM
    joejoepepitone joejoepepitone Dec 9, 2014 3:11 PM Flag

    i think you can get all the shares you want under $.20 in the near future….assuming you want go back in.

  • Reply to

    MRA Research

    by theeckman1 Dec 5, 2014 2:58 PM
    joejoepepitone joejoepepitone Dec 9, 2014 10:58 AM Flag

    Article in today's Seeking Alpha, discussing the paid for pump article, and their prediction $.01. Bottom line, management not coming clean, and shareholders are in for a very rude awakening.

  • Reply to


    by joejoepepitone Feb 19, 2015 11:58 AM
    joejoepepitone joejoepepitone Feb 19, 2015 3:52 PM Flag

    This European office was opened and is maintained purely for the convenience of Dr. Lowe.

  • Well done report with short term price target of $.71. Actually I think they are being conservative. I believe there will be more announcements coming out when the HIPP deal closes. I assume they can't specify an exact date for that, since it is coming out of the bankruptcy court. Additional to the expected valuation is the potential of the patent family. There is a reason that Jerry has an expensive, dedicated resource on this issue. I would not be surprised if Jerry is thinking about the acquisition of additional patents in addition to organic growth of the patent estate.
    I think if Jerry can do a seamless integration (dramatically cut HIPP costs and improve profitability) and begin to show sales traction with the new account roster, then by Q4 reporting (Q1 2016) we can double again to $1.50 (price not reflective of stock reverse). All execution now.

  • joejoepepitone by joejoepepitone Feb 19, 2015 11:58 AM Flag

    Need clarity on AVXL and future deals. I had thought that these assets would be either partnered or sold to a Quest, Becton, etc. and that THEY would be marketing/distributing these products/services to Biotech/BP. Now it seems that AMBS is filling that role? Are they really equipped to be the marketers here? Will Gerald be on the phone all day doing this? I have not seen anything described as a sales force to fulfill this role. I am not clear on what is going on here. Anyone care to offer an explanation? Thanks in advance.

  • joejoepepitone joejoepepitone Feb 6, 2015 12:06 AM Flag

    IR Firm is now supporting. A good sign. Frank is frugal, therefore there will be news. Market voting thumbs up for the time-being.

  • Reply to

    On Deck and ready to bat: Chromadex

    by joejoepepitone Feb 10, 2015 1:14 PM
    joejoepepitone joejoepepitone Feb 10, 2015 4:16 PM Flag

    Probably, but I think a/some contracts/revenue generating events, would be even more desirable at this time. They need to demonstrate a solid foundation for growth over time.

  • joejoepepitone by joejoepepitone Feb 27, 2015 10:42 PM Flag

    Listened to CC. Have no idea what the future holds, although I had hoped he would have provided a bit more understanding of the value of the Chinese partner (how that would work), and the value of ACKinetics. I am a bit surprised that management believes that branding lighting products with an electric flooring brand (HOOVER) creates any benefit whatsoever. What are they thinking. I don't get it. And they are willing to stake a huge amount of cost, upheaval to their inventory/logistics, customer relations, retail positioning, sales execution, all for a change to the HOOVER name? Hunh? This was a risky investment. It got much more risky. I would only take an investment if ACKinetics R&D got incorporated in a big way in truly ground-breaking products. Until that happens, this is worse than Vegas odds. Hoping that ACK can be the hero here.

  • Reply to

    Low Revenue

    by frank1a Nov 27, 2014 5:56 AM
    joejoepepitone joejoepepitone Dec 4, 2014 11:09 AM Flag

    There was a "research report" out yesterday. Nothing new in it that wasn't in CEO letter. It is meant to create an upside bounce before the pricing for the stock split. Highly questionable report. The company issuing the report may receive compensation or take shares before they publish their report. Wow, talk about an unbiased source! They claimed a $5 price target….without any financial tables to explain how they got their number. They did not discuss 1 single financial element of the company's path to profitability. One number did stick out in my mind, the outstanding debt is equal to the market cap. I noticed that the CEO said NADA regarding the company financials and how it remains solvent. I believe that this is a temporary high, and is more fairly valued at 1/3 of the current price, as an extremely high risk situation. Debt is ceiling high and going higher every quarter. Debt now close to 2 years of revenue. How do they begin to close this gaping hole? No discussion of how they even achieve break-even operations. What is Silverman doing now that he left the CEO spot? Chairman means he is watching his stock position..not sure of day-to-day involvement.

  • Reply to

    Tax Loss Selling

    by joejoepepitone Nov 14, 2014 7:53 PM
    joejoepepitone joejoepepitone Dec 11, 2014 11:32 PM Flag

    Wow, this is falling bayonet. How low do we go from here? I'll wager by 12/31/14 we hit $.40-$.50? Don't know if it's worth putting more into this sorry investment at those prices. Loses at tax loss time ...can't stop the bleeding with slow mo R&D programs.

8.15+0.05(+0.62%)Feb 27 3:49 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
PulteGroup, Inc.
NYSEFri, Feb 27, 2015 4:02 PM EST